Plantar exfoliation and desquamation during efalizumab therapy.
Adíşen
E
E
Gürer
M A
MA
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D005528:Foot / Q000473:pathology; D006801:Humans; D011565:Psoriasis / Q000188:drug therapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab